Immunotherapy with NGcGM3/VSSP and nimotuzumab in metastatic triple negative breast cancer patients. Phase I/II
Latest Information Update: 14 Oct 2020
At a glance
- Drugs N-glycolyl GM3 vaccine (Primary) ; Nimotuzumab (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 16 Nov 2016 New trial record